The Oncology Institute, Inc. (TOI)
NASDAQ: TOI · IEX Real-Time Price · USD
0.524
+0.004 (0.77%)
At close: Jul 19, 2024, 4:00 PM
0.560
+0.036 (6.87%)
Pre-market: Jul 20, 2024, 9:28 AM EDT

Company Description

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.

The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.

It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.

It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California.

The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

The Oncology Institute, Inc.
The Oncology Institute logo
Country United States
Founded 2007
Industry Medical Care Facilities
Sector Healthcare
Employees 800
CEO Dr. Daniel Virnich FACHE, M.B.A., M.D.

Contact Details

Address:
18000 Studebaker Rd, Suite 800
Cerritos, California 90703
United States
Phone 562-735-3226
Website theoncologyinstitute.com

Stock Details

Ticker Symbol TOI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001799191
CUSIP Number 68236X100
ISIN Number US68236X1000
Employer ID 84-3562323
SIC Code 8011

Key Executives

Name Position
Dr. Daniel Virnich FACHE, M.D., MBA Chief Executive Officer
Richard Alan Barasch Executive Chairman of the Board
Mihir Arunkumar Shah CPA Chief Financial Officer and Principal Accounting Officer
Hilda Agajanian M.B.A. Founder and Chief Growth Officer
Dr. Richy Agajanian M.D. Founder and Chief Clinical Officer
Jeremy N. Castle M.B.A. Chief Operations Officer
Rakesh Singh M.B.A. Director of Technology
Mark Hueppelsheuser Esq. General Counsel
Khurrum Shah J.D., M.B.A. Senior Vice President of Compliance
Julie Korinke Director of Marketing and Communications

Latest SEC Filings

Date Type Title
Jun 21, 2024 8-K Current Report
Jun 13, 2024 8-K Current Report
Jun 3, 2024 UPLOAD Filing
May 22, 2024 10-Q/A [Amend] Quarterly report
May 22, 2024 10-K/A [Amend] Annual report
May 15, 2024 UPLOAD Filing
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
May 2, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 2, 2024 DEF 14A Other definitive proxy statements